Baylor College of Medicine Human Genome Sequencing Center adopts Olink® Explore HT proteomics platform
08 August 2023 - 10:00PM
Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK) today announced
that the Baylor College of Medicine Human Genome Sequencing Center
(BCM-HGSC) has selected the Olink Explore platform as a proteomics
component of their world-class multiomics offering.
Understanding the complex biological mechanisms
of human diseases is essential to identifying effective new
therapeutic strategies. The addition of Olink proteomic technology
enables a more thorough understanding of the intricate connections
between genes, proteins, and diseases that will lead to improved
diagnostics, targeted therapies and the advancement of precision
and personalized medicine.
“We are immensely pleased to see the Olink
Explore HT platform implemented at one of the world’s leading
multiomic research centers,“ said Jon Heimer, CEO,
Olink Proteomics. “The massive genomic sequencing and
automation capabilities of the BCM-HGSC unlocks a unique
opportunity for proteogenomic research at scale. We look forward to
seeing our tools applied across a broad spectrum of new therapeutic
research fields to enhance the existing knowledge of molecular
pathways involved in the development, progression, and outcome of
disease.”
Other large-scale research programs, like the UK
Biobank health study, have demonstrated how Olink Explore enables a
more complete understanding of the molecular basis of disease. With
the addition of Olink proteomics technology, the BCM-HGSC further
strengthens its ability to offer unique multiomics capabilities for
large population-scale health studies.
“Technology development and the adoption of new
methods remains a priority at the HGSC, and we are excited to
incorporate Olink’s technology into our portfolio,” said
Richard Gibbs, Ph.D. Director, Human Genome Sequencing
Center and Wofford Cain Professor of Molecular & Human
Genetics, Baylor College of Medicine.
“The ability to perform high-throughput proteomics opens many
possibilities for current and future studies. This technology
provides a natural extension from traditional genomic research by
providing data that points to the impact of genetic variation on
function. A comprehensive, multiomic approach will be needed to
determine the mechanism of action of many genetic diseases and is
essential for guiding effective prevention and treatment.”
The Olink Explore platform represents the
cutting edge in proteomic technology. Olink Explore HT is the
company's latest solution for high-throughput proteomics,
delivering unmatched specificity, scalability, and simplicity. With
a completely reimagined and streamlined workflow, Olink Explore HT
allows scientists to accurately measure over 5,300 proteins using
only 2µl of sample. By combining Olink PEA technology with an NGS
readout of relative protein concentrations each thoroughly
validated assay maintains the exceptional standards of specificity
and sensitivity that Olink users have come to trust.
More details are available on the Olink
website.
Investor contact Jan Medina, CFAVP Investor
Relations & Capital MarketsMobile: +1 617 802
4157jan.medina@olink.com
Media contact Michael B. Gonzales, PhDVP Global
MarketingMobile: +1 415 308 6467michael.gonzales@olink.com
About Olink Holding AB (publ) (Nasdaq: OLK) is
a company dedicated to accelerating proteomics together with the
scientific community, across multiple disease areas to enable new
discoveries and improve the lives of patients. Olink provides a
platform of products and services which are deployed across major
pharmaceutical companies and leading clinical and academic
institutions to deepen the understanding of real-time human biology
and drive 21st century healthcare through actionable and impactful
science. The Company was founded in 2016 and is well established
across Europe, North America and Asia. Olink is headquartered in
Uppsala, Sweden.
Forward-Looking StatementsThis release may
contain forward-looking statements within the meaning of applicable
securities laws, including the U.S. Private Securities Litigation
Reform Act of 1995, as amended, including, without limitation,
statements regarding Olink’s strategy, business plans and focus.
The words “may,” “will,” “could,” “would,” “should,” “expect,”
“plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,”
“project,” “potential,” “continue,” “target” and similar
expressions are intended to identify forward-looking statements,
although not all forward-looking statements contain these
identifying words. Any forward-looking statements in this press
release are based on management’s current expectations and beliefs
as of the date hereof and are subject to a number of risks,
uncertainties and important factors that may cause actual events or
results to differ materially from those expressed or implied by any
forward-looking statements contained in this press release,
including, without limitation, those related to Olink’s business,
operations, supply chain, strategy, goals and anticipated
timelines, including for the delivery of Olink Explore 3072 and the
expansion of the Explore platform, competition, and other risks
identified in the section entitled “Risk Factors” in Olink’s
Registration Statement on Form F-1, as amended (File No.
333-253818) filed with the U.S. Securities and Exchange Commission
(SEC) and in the other filings, reports, and documents Olink files
with the SEC from time to time. Olink expressly disclaims any
obligation to update any forward-looking statements in this release
to reflect any change in its expectations with regard thereto or
any change in events, conditions or circumstances on which any such
statement is based, unless required by law or regulation.
Olink Holding AB (NASDAQ:OLK)
Historical Stock Chart
From Apr 2024 to May 2024
Olink Holding AB (NASDAQ:OLK)
Historical Stock Chart
From May 2023 to May 2024